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Abstract
Background: Periprosthetic joint infections (PJI) are often treated by two stage exchange with the use of an
antibiotic impregnated spacer. Most of the two-stage exchange algorithms recommend the implantation of an
antibiotic-impregnated spacer during the first stage for a period of 2–24 weeks before reimplantation of the new
prosthesis. For the spacer to have a therapeutic effect, the local antibiotic concentration must be greater than the
minimal inhibition concentration (MIC) against the pathogens causing the PJI. It must remain so for the entire
spacer period, otherwise recurrence of infection or resistances might occur. The question as to whether a sufficient
concentration of antibiotics in vivo is reached for the entire spacer period has not been answered satisfactorily.
Case presentation: We here present a case of a histologically confirmed chronic PJI 20 month after primary
arthroplasty. The primary knee arthroplasty was performed due to osteoarthritis of the joint. Initial assessment did
not detect a causative pathogen, and two stage exchange with a vancomycin-gentamycin impregnated spacer was
performed. At the time of reimplantation, sonication of the explanted spacer revealed a multi-resistant strain of
staphylococcus epidermidis on the device and in the joint. Adaption of the therapy and prolonged treatment
successfully eradicated the infection.
Conclusion: According to the authors’ knowledge, the case presented here confirms for the first time the surface
contamination (proven through sonication) of a vancomycin-/gentamicin- impregnated Vancogenx®-spacer with a
MRSE after ten weeks of implantation.
This case study demonstrates the difficulties still associated with the diagnostics of PJI and the published different
two stage treatment regimes with the use of antibiotic impregnated spacers.
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Background
The two-stage exchange arthroplasty remains the pre-
ferred surgical treatment for chronic periprosthetic joint
infection (PJI) [1,2]. Most of the two-stage exchange al-
gorithms recommend the implantation of an antibiotic-
impregnated spacer during the first stage for a period of
2–24 weeks before reimplantation of the new prosthesis
[3-5]. This procedure is supposed to provide an initially
high local release of antibiotics, then decreasing continu-
ously over time [6].
There have been numerous in-vitro studies investiga-
ting the release of different antibiotics from antibiotic-
impregnated polymethyl-methacrylate (PMMA) spacers
[7-9]. The question as to whether a sufficient concen-
tration of antibiotics in vivo is reached for the entire
spacer period has not been answered satisfactorily. Pre-
vious in vivo studies have shown that only a minor por-
tion of the antibiotics incorporated in the bone cement
is really eluted. Furthermore, some of these studies even
show conflicting results [10,11]. The elution of antibi-
otics from the bone cement does not necessarily reflect
the tissue concentrations. Different antibiotics are re-
leased at different rates and in a different way from the
bone cement according to their physicochemical charac-
teristics, maybe even causing synergistic effects and an
improved elution when combining two water-soluble an-
tibiotics in bone-cement [6].
The combination of vancomycin and an aminoglyco-
side (gentamycin or tobramycin) has a broad spectrum
of activity, covering also a variety of gram-positive bac-
teria, such as MRSA and many staphylococcus epidermi-
dis strains [6]. On the other hand, not all gram- negative
bacteria are treated effectively [12]. Other combinations
of antibiotics are also possible, but it must be kept in
mind that missing antibiotics into the bone cement for
custom made spacer is usually considered off-label use
of the drug. Antibiotic-impregnated spacers are also
commercially available (e.g. Vancogenx®, Merete GmbH,
Berlin, Germany). They have, in contrast to custom made
spacers, the advantage of a known chemical and mecha-
nical characteristics [13,14].
For the spacer to have a therapeutic effect, the local
antibiotic concentration must be greater than the min-
imal inhibition concentration (MIC) against the patho-
gens causing the PJI. It must remain so for the entire
spacer period, otherwise recurrence of infection or resis-
tances might occur. Therefore, the local antibiotic con-
centration in the tissue surrounding the spacer should
be greater than the MIC previously determined for the
pathogen that is responsible for the PJI [11,15].
In this case report, we describe the first known case
of a foreign body infection, caused by a multi-resistant
staphylococcus epidermidis (MRSE) on a gentamicin-
vancomycin-impregnated spacer. The spacer was in situ
for 10 weeks due to a chronic PJI of the knee, and the
pathogen was detected through sonication after explan-
tation of the spacer.
Case presentation
We present the case of a 52-year old male patient with a
histologically confirmed chronic PJI of the knee but
without microbiological detection of a pathogen, under-
going a two-stage exchange arthroplasty in our hospital.
The diagnosis of PJI used in the presented case was
modified to the criteria described by Zimmerli and
Trampuz et al. [4,16,17].
A primary cemented knee arthroplasty with a genta-
mycin loaded bone cement was performed due to os-
teoarthritis of the joint. The initial postoperative period
was uneventful, but the patient presented himself after
20 month with pain in the operated joint. Besides per-
sistent swelling and local hyperthermia, there were no
systemic signs of an infection (normal leukocyte count
and normal serum level of C-reactive protein (CRP)). Pa-
tient’s comorbidities are a diabetes type II, a chronic ob-
structive bronchitis, obesity, a arterial hypertonica and a
nicotine abuse.
A synovial joint fluid aspiration was performed under
aseptic surgical conditions. Even after long-term culture
incubation of 14 days, no pathogen was detected. The
total synovial leukocyte count had been 353 cells/μl with
a neutrophil percentage of 34% (PMN%).
Revision surgery of the knee joint was performed, re-
vealing signs of an infection, including presence of puru-
lence and infection-associated osteolysis, particularly in
the medial and lateral femoral condyles.
Based on these findings, the present total knee pros-
thesis was explanted, thorough surgical debridement was
performed, and a Vancogenx®-spacer (Merete Medical
GmbH, Berlin, Germany) with vancomycin- and genta-
mycin supplements (1.8 g each per spacer) was implan-
ted. Intraoperatively, tissue samples were taken from
representative infected areas (from tibia and femur com-
ponents, tibial and femoral medullar cavities, and joint
capsules). Each of these tissue samples were divided in
half, one part for microbiological, long-term incubation
(10-14d), the other for histological analysis (classification
of periprosthetic membranes according to Morawietz
et al. [18]). From these five tissue samples, none showed
positive for a pathogen in microbiology. Histologically,
the periprosthetic membrane was classified to be of the
infectious type (Morawietz type II [18]).
In accordance to the standards of our institution, and
derived from an analysis of causative pathogens in our
patients, an empirical antibiotic therapy was started, with
vancomycin and piperacillin/tazobactam intravenously,
and rifampicin orally, for 14 days.
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The postoperative hospital stay was without further
complications; after two weeks, therapy was changed to
moxifloxacin and rifampicin orally and continued for an
additional four weeks. Antibiotics were stopped and after
another two weeks, joint fluid was aspirated under ster-
ile surgical conditions. The cell count yielded 1380 Leu-
kocytes/μl with 42% polymorph nuclear neutrophils, and
microbiological testing in long-term incubation again
turned out negative. After another two weeks, in total
ten weeks after explantation, the same surgeon performed
the reimplantation of a cemented rotating hinge knee
prosthesis using vancomycin/gentamycin loaded cement
for the undersurface (RT Plus Solution modular; Smith &
Nephew, Marl, Germany). Intraoperatively, no macro-
scopic signs of infection could be detected; in particular,
in contrast to the explantation, the joint fluid was clear
and the bone quality, underneath the femoral as well as
tibial spacer components, was no longer gave the impres-
sion of being infected. Again several tissue samples were
taken as mentioned afore for microbiological incuba-
tion and histological examination. Additionally, the ex-
planted spacer was sent in for sonication (BactoSonic®
14.2, Bandelin electronic GmbH & Co. KG, Berlin,
Germany), as described by Trampuz et al. [19]. Post-
operatively, antibiotics were started prophylactical, again
with vancomycin and piperacillin/tazobactam intraven-
ously and rifampicin p.o.
In the sonication fluid, a multi-resistant staphylococ-
cus epidermidis (MRSE) was detected, also being re-
sistant to rifampicin, as proof of a bacterial growth on
the Vancogenx®-spacer. Identification was performed by
MALDI-TOF (Biomérieux, Nürtingen, Germany) and
antibiotic susceptibility was performed by VITEK-2
(Biomérieux, Nürtingen, Germany). The MIC values were
interpreted susceptible by European Committee on Anti-
microbial Susceptibility Testing (EUCAST, Version 2.0
2012) as follows: Doxycyclin (1 mg/l), vancomycin (1 mg/l),
linezolid (2 mg/l) and daptomycin (≤ 0.5 mg/l).
This MRSE would later show in three of the five tissue
samples from the reimplantation surgery as well. Be-
cause of the level of resistance, the antibiotic therapy
was adapted and changed to daptomycin in the dosage
of 10 mg/kg KG, administered for a total of 14 days
intravenously. Afterwards, an oral therapy with Linezolid
was continued for 28 more days. During the follow-up
period of one year after reimplantation, the patient did
not present any local or systemic signs of infection. Se-
rum CRP and leukocyte count remain negative, making
the patient currently “highly probably infection free”, ac-
cording to the criteria of Laffer et al. [16].
Discussion
According to the authors’ knowledge, the case presented
here confirms for the first time the surface contamination
(proven through sonication) of a vancomycin-/gentami-
cin- impregnated Vancogenx®-spacer with a MRSE after
ten weeks of implantation.
In a patient presenting 20 month after the primary
arthroplasty with a painful joint, PJI must be considered
as a differential diagnosis, even when systemic signs of
infection are missing. Infections at this time point can
be either hematogenous acute infections or a chronic
primary low-grade infection. The negative cell count in
the synovial fluid, as well as the lack of a systemic in-
flammatory response is pointing towards a low grade in-
fection. During the first revision, considering the local,
intraoperative findings, the surgeon decided on explant-
ation and two-step exchange.
The choice to use a Vancogenx®-spacer seems, not as-
suming the presence of a difficult-to-treat pathogen at
that time, sensible. By combining vancomycin and genta-
micin, the most common pathogens of a chronic PJI
(among others, coagulase-negative staphylococcus and
propioni bacteria) are covered and treated. Even though
our own analysis shows a considerably high rate of multi-
resistant coagulase-negative staphylococcus and app.
30% gram-negative pathogens in our patient collective,
vancomycin and gentamycin remain the first line local
treatment in our institution [20,21]. To avoid the rapid de-
velopment of bacterial resistances, especially in staphylo-
cocci, antibiotic combination therapies should be favored
over monotherapies.
For combining vancomycin and gentamicin, synergistic
effects have already been proven with regard to efficacy
and improved release kinetics in local drug delivery.
The emergence of the highly resistant MRSE in the
current case could be explained by an already existing
gentamicin-resistant pathogen at the point of explant-
ation. Especially the use of gentamicin-containing PMMA
in the primary arthroplasty could induce such resistances
through the sub-therapeutic release of the antibiotic over
the 20 month period, as previously observed by Neut et al.
[22]. If this was also the case in the patient presented
herein cannot be determined from the records.
The negative microbiological findings in the preopera-
tive joint aspiration, as well as in the intraoperative spec-
imens from the explanation give rise to discussion, for
the local site findings, the positive histology and the
clear signs of an infection intraoperatively all clearly poin-
ted to the presence of a PJI. PJI without bacterial growth
are indicated in the literature with 10–26.5% [4,21]. The
reasons for this are numerous. The patient did not receive
any antibiotic therapy prior to the revision, ruling out this
common source of false negatives. Other reasons include
a low inoculum, adherent bacteria on the implant, difficult
to identify bacteria (e.g. “small colony variants” (SCV)), as
well as logistic (storage and transportation of the speci-
men) as well as technical problems, or insufficient testing
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in the laboratory [23]. The sonication of the primary im-
plant–this procedure was, at that point, not yet available
to our institution–might have improved the microbio-
logical diagnostics. Trampuz et al. [19] proved that, com-
pared to the culture of periprosthetic tissue samples alone,
a significantly higher sensitivity can be reached through
this method.
The second possibility for the emergence of the
gentamicin-resistance of the pathogen is the rather long
implantation time of ten weeks, inducing resistances
through sub-therapeutic concentrations of the antibio-
tics in the surrounding tissue. Many acknowledged ther-
apy regimes include an implantation time of antibiotic-
impregnated spacer also in this length; nevertheless, the
scientific data is mixed regarding the release of thera-
peutic substances over such a long time period. Most
data on this matter is derived from in-vitro release kinet-
ics. They do not, however, take into account the mul-
tifaceted interactions between the local anti-microbial
therapy, the causative bacteria, the properties of the
PMMA, the patient’s immune system and an additional
systematic antibiotic therapy. More studies have proven
high concentrations of antibiotics in the drainage fluid
during the first few days after the implantation of an
antibiotic-impregnated spacer [14,24,25]. Decreasing con-
centrations at more therapeutic doses could be docu-
mented up to 7 days after spacer implantation [14]. Masri
et al. [10] showed a release of tobramycin and vancomycin
from the spacer over a time period of an average of
118 days, Hsieh et al. [26] for vancomycin and azetreonam
of an average of 107 days. Bertazzoni Minelli et al. [6]
showed a high initial gentamycin- and also vancomycin-
release in the early phase after implantation, followed by a
lower, but constant release over the time period of 3–
6 months. It must be critically noted that the previously
named studies determine either the intraarticular anti-
biotic concentration or the in-vitro release of the spacer
after explantation. In contrast, Fink and colleagues [11]
were able to prove that therapeutic concentrations above
the MIC inside of the periprosthetic tissue could be de-
tected after an implantation time of 6 weeks both for
copal cement (gentamycin and clindamycin supplement)
as well as for copal cement spacer with vancomycin sup-
plement. Again, in-vitro studies of explanted spacers also
revealed major differences in the residual amount of anti-
biotics, in the effectiveness and in release characteristics at
identical implantation times. The discrepancy of these re-
sults is still to a great extent unclear. The local tissue
blood supply as well as the pH-value of the tissue are con-
sidered relevant factors, and also the covering of the sur-
face of the spacer with scar tissue [14,27].
Therapy algorithms are clinically established and ac-
knowledged; they include a sterile joint aspiration during
the implant-free interval and after an antibiotic-free
interval of at least two weeks. Only after negative results
of long-term incubation, the reimplantation of the new
prosthesis can be considered. This procedure has the de-
cisive disadvantage that no systematic antibiotic protec-
tion is present at a time of continually decreasing local
antibiotic release from the spacer. In the current case,
over a time period of 4 weeks, oral, systemic antibiotics
were stopped before the new prosthesis was reimplanted,
while the spacer was already in place for six weeks. The
value of this additional joint puncture must be critically
discussed, since every fifth PJI is missed through joint
aspiration alone, anyhow [28]. Anagnostakos et al. [14]
even recommend an adaptation in dosage of the system-
atic antibiotic therapy, in order to avoid the creation of
multi-resistant strains. Alternative therapy concepts in-
clude shorter time periods under continual i. v.-antibiotic
therapy or the exchange of the antibiotic-impregnated
spacer to ensure high local drug levels [4]. With the know-
ledge of the pathogen findings in the current case, a two-
step process without spacer and the continuous intraven-
ous application of antibiotics over a time period of
6 weeks, corresponding to published recommendations
with multi-resistant bacteria, seems another sensible treat-
ment option [4].
In the current case, rifampicin was used in the em-
pirical therapy regime right after the explantation of
the primary prosthesis. It is still unclear if the use of
a biofilm-effective antibiotic (rifampicin, in the present
case) makes sense combined with a spacer at all. With the
removal of the prosthesis and extensive debridement, bio-
films should be reduced to a minimum, and antibiotics
such as vancomycin or piperacillin should also be effec-
tive. Clauss et al. [29] identified that the systemic rifampi-
cin therapy, in combination with a spacer, is a possible
cause for subsequent rifampicin-resistances (OR 7.9; p =
0.057). In the case presented here, this was also seen. It
should therefore be considered to withhold the biofilm-
effective antibiotics until reimplantation.
Conclusion
In summary, the current case impressively presents the
problems regarding the diagnosis and therapy of PJI.
Differential diagnostics of a low grade infection can be
difficult and different tests can yield conflicting results, in-
cluding false negatives and false positives. New methods–
like the sonication–can essentially improve perioperative
diagnosis. The use of spacers includes advantages as well
as disadvantages, and little is known about the in-vivo ef-
fect of the incorporated antibiotics. Different regimes in
treatment and the perfect time point and setting for the
reimplantation yet remain to be determined and tested
in clinical practice. Prospective, controlled therapy stu-
dies are necessary to help solve these important clinical
problems.
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